medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-553Research ArticleСтатьиГастроэнтерологические заболевания у пациентов с ожирением. Осведомленный врач, защищенный пациентGastroenterological diseases in patient with obesity. Knowledgeable doctor, protected patientТихоновС. В.TikhonovS. V.noemail@neicon.ruДеккановаВ. Д.DekkanovaV. D.noemail@neicon.ruАлиеваМ. К.AlievaM. K.noemail@neicon.ruДаниловВ. Р.DanilovV. R.noemail@neicon.ruФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University n.a. I.I. MechnikovRussian Federation20180503201817Практическая гастроэнтерология1016Copyright © Тихонов С.В., Декканова В.Д., Алиева М.К., Данилов В.Р., 20182018Тихонов С.В., Декканова В.Д., Алиева М.К., Данилов В.Р.Tikhonov S.V., Dekkanova V.D., Alieva M.K., Danilov V.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/553

В обзорной статье исследуется встречаемость у пациентов с ожирением различных гастроэнтерологических заболеваний - гастроэзофагеальной рефлюксной болезни, хронического гастрита, желчнокаменной болезни, рака желчного пузыря, неалкогольной жировой болезни печени, неалкогольной жировой болезни поджелудочной железы, доброкачественных и злокачественных новообразований слизистой толстой кишки. Особое внимание уделяется эпидемиологическим данным, особенностям течения данных патологий, прогнозу, механизмам влияния ожирения на патогенез вышеперечисленных заболеваний, подходам к лечению.

The incidence of different gastroenterological diseases (gastroesophageal reflux disease, chronic gastritis, gallstones, gallbladder cancer, non-alcoholic fatty liver disease, non-alcoholic fatty pancreas disease, neoplasms of the colonic mucosa) in obese patients is investigated in a review article. There are the epidemiological dates, the flow characteristics of these pathologies, forecast, mechanisms of influence of the obesity on the pathogenesis of the gastroenterological diseases, the approaches of treatment.

ожирениегастроэзофагеальная рефлюксная болезньнеалкогольная жировая болезнь печенинеалкогольная жировая болезнь поджелудочной железыколоректальный ракobesitygastroesophageal reflux diseasenon-alcoholic fatty liver diseasenon-alcoholic fatty pancreas diseaseneoplasms of the colonic mucosacolorectal cancerReferenceshffp: //www.who.inf/en Обращение от 22.11.2017.hffp: //www.who.inf/en Обращение от 22.11.2017.Andres A., Michael C. Gastrointestinal Morbidity in Obesity. Ann N Y Acad Sci. 2014; 1311: 42-56.Andres A., Michael C. Gastrointestinal Morbidity in Obesity. Ann N Y Acad Sci. 2014; 1311: 42-56.Simanenkov V. I., Tikhonov S. V., Dekkanova V. D. Irritable Bowel Syndrome in a Patient with Obesity, Accident or Regularity? Медицинский алфавит. 2017; 40(4): 17-23.Simanenkov V. I., Tikhonov S. V., Dekkanova V. D. Irritable Bowel Syndrome in a Patient with Obesity, Accident or Regularity? Медицинский алфавит. 2017; 40(4): 17-23.Faloia E., Michetti G., De Robertis M., et al. Inflammation as a Link between Obesity and Metabolic Syndrome. Journal of Nutrition and Metabolism. 2012; 2012: 7-16.Faloia E., Michetti G., De Robertis M., et al. Inflammation as a Link between Obesity and Metabolic Syndrome. Journal of Nutrition and Metabolism. 2012; 2012: 7-16.Stienstra R., Tack C., Kanneganti T-D., et al. The inflammasome puts obesity in the danger zone. Cell metabolism. 2012; 15(1): 10-8.Stienstra R., Tack C., Kanneganti T-D., et al. The inflammasome puts obesity in the danger zone. Cell metabolism. 2012; 15(1): 10-8.Lagergren J. Influence of obesity on the risk of esophageal disorders. Nature reviews Gastroenterology & hepatology. 2011; 8(6): 340-7.Lagergren J. Influence of obesity on the risk of esophageal disorders. Nature reviews Gastroenterology & hepatology. 2011; 8(6): 340-7.Anggiansah R., Sweis R., Anggiansah A., et al. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics. 2013; 37(5): 555-563.Anggiansah R., Sweis R., Anggiansah A., et al. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics. 2013; 37(5): 555-563.Crowell M., Bradley A., Hansel S., et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol. 2009; 104(3): 553-559.Crowell M., Bradley A., Hansel S., et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol. 2009; 104(3): 553-559.Nilsson M., Lundegârdh G., Carling L., et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scandinavian journal of gastroenterology. 2002; 37(6): 626-30.Nilsson M., Lundegârdh G., Carling L., et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scandinavian journal of gastroenterology. 2002; 37(6): 626-30.Nilsson M., Johnsen R., Ye W., et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA: the journal of the American Medical Association. 2003; 290(1): 66-72.Nilsson M., Johnsen R., Ye W., et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA: the journal of the American Medical Association. 2003; 290(1): 66-72.Nordenstedt H., Zheng Z., Cameron A., et al. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008; 134(4): 921-8.Nordenstedt H., Zheng Z., Cameron A., et al. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008; 134(4): 921-8.Hampel H., Abraham N., El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of internal medicine. 2005; 143(3): 199-211.Hampel H., Abraham N., El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of internal medicine. 2005; 143(3): 199-211.Cai N., Ji G. Z., Fan Z. N., et al. Association between body mass index and erosive esophagitis: a meta-analysis. World J Gastroenterol. 2012; 18(20): 2545-53.Cai N., Ji G. Z., Fan Z. N., et al. Association between body mass index and erosive esophagitis: a meta-analysis. World J Gastroenterol. 2012; 18(20): 2545-53.Singh S., Sharma A., Murad M., et al. Central Adiposity Is Associated With Increased Risk of Esophageal Inflammation, Metaplasia, and Adenocarcinoma: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2013. 15: 18-23Singh S., Sharma A., Murad M., et al. Central Adiposity Is Associated With Increased Risk of Esophageal Inflammation, Metaplasia, and Adenocarcinoma: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2013. 15: 18-23El-Serag H., Kvapil P., Hacken-Bitar J., et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005; 100(10): 2151-2156.El-Serag H., Kvapil P., Hacken-Bitar J., et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005; 100(10): 2151-2156.Kendall B., Macdonald G., Hayward N., et al. Leptin and the risk of Barrett’s oesophagus. Gut. 2008; 57(4): 448-54.Kendall B., Macdonald G., Hayward N., et al. Leptin and the risk of Barrett’s oesophagus. Gut. 2008; 57(4): 448-54.Rubenstein J., Kao J., Madanick R., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut. 2009; 58(12): 1583-9.Rubenstein J., Kao J., Madanick R., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut. 2009; 58(12): 1583-9.Ryan A., Duong M., Healy L., et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer epidemiology. 2011; 35(4): 309-19.Ryan A., Duong M., Healy L., et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer epidemiology. 2011; 35(4): 309-19.Ogunwobi O., Beales I. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. British journal of biomedical science. 2008; 65(3): 121-7.Ogunwobi O., Beales I. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. British journal of biomedical science. 2008; 65(3): 121-7.Eslick G. Gastrointestinal symptoms and obesity: a meta-analysis. Obes Rev. 2012; 13(5): 469-79.Eslick G. Gastrointestinal symptoms and obesity: a meta-analysis. Obes Rev. 2012; 13(5): 469-79.Delgado-Aros S., Locke G., Camilleri M., et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. The American journal of gastroenterology. 2004; 99(9): 1801-6.Delgado-Aros S., Locke G., Camilleri M., et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. The American journal of gastroenterology. 2004; 99(9): 1801-6.Yamamoto S., Watabe K., Takehara T. Is obesity a new risk factor for gastritis? Digestion. 2012; 85(2): 108-10.Yamamoto S., Watabe K., Takehara T. Is obesity a new risk factor for gastritis? Digestion. 2012; 85(2): 108-10.Kim H., Yoo T., Park D., et al. Influence of overweight and obesity on upper endoscopic findings. Journal of gastroenterology and hepatology. 2007; 22(4): 477-81.Kim H., Yoo T., Park D., et al. Influence of overweight and obesity on upper endoscopic findings. Journal of gastroenterology and hepatology. 2007; 22(4): 477-81.Yamamoto S., Watabe K., Tsutsui S., et al. Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci. 201; 56(8): 2354-60.Yamamoto S., Watabe K., Tsutsui S., et al. Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci. 201; 56(8): 2354-60.Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Current pharmaceutical design. 2010; 16(17): 1896-901.Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Current pharmaceutical design. 2010; 16(17): 1896-901.Yang P., Zhou Y., Chen B., et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. European journal of cancer (Oxford, England: 1990). 2009; 45(16): 2867-73.Yang P., Zhou Y., Chen B., et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. European journal of cancer (Oxford, England: 1990). 2009; 45(16): 2867-73.Ericksen R., Rose S., Westphalen C., et al. Obesity accelerates Helicobacter felis-in-duced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut. 2013; 22(4): 477-81.Ericksen R., Rose S., Westphalen C., et al. Obesity accelerates Helicobacter felis-in-duced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut. 2013; 22(4): 477-81.BellentaniS., Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of hepatology. 2009; 8(1): 8-12.BellentaniS., Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of hepatology. 2009; 8(1): 8-12.Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of internal medicine. 2000; 132(2): 112-7.Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of internal medicine. 2000; 132(2): 112-7.Attar B. M., Van Thiel D. H. Current concepts and management approaches in nonalcoholic fatty liver disease. Scientific World Journal. 2013; 2013: 10-14.Attar B. M., Van Thiel D. H. Current concepts and management approaches in nonalcoholic fatty liver disease. Scientific World Journal. 2013; 2013: 10-14.Ivashkin V. T., Drapkina O.M. The prevalence of non-alcoholic fatty liver disease in Russian Federation. UEGW/WCOG GASTRO. 2009; Nov.: 21-25.Ivashkin V. T., Drapkina O.M. The prevalence of non-alcoholic fatty liver disease in Russian Federation. UEGW/WCOG GASTRO. 2009; Nov.: 21-25.Rahman R. N., I J. A. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: a population based study. Hepatology (Baltimore). 2012; 56: 241-243.Rahman R. N., I J. A. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: a population based study. Hepatology (Baltimore). 2012; 56: 241-243.Noureddin M., Lam J., Peterson M. R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58: 1930-1940.Noureddin M., Lam J., Peterson M. R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58: 1930-1940.Angulo P., Hui J. M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45: 846-854.Angulo P., Hui J. M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45: 846-854.Chen J., Talwalkar J. A., Yin M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011; 259: 749-756.Chen J., Talwalkar J. A., Yin M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011; 259: 749-756.Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. J Hepatology. 2013; 59: 859-871.Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. J Hepatology. 2013; 59: 859-871.Williams C. D., Stengel J., Asike M. I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124-131.Williams C. D., Stengel J., Asike M. I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124-131.Yang J. D., Abdelmalek M. F., Pang H., et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014; 59: 1406-1414.Yang J. D., Abdelmalek M. F., Pang H., et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014; 59: 1406-1414.Zelber-Sagi S., Lotan R., Shlomai A., et al. Predictors for incidence and remission of NAFLD in the general population during a sevenyear prospective follow-up. J Hepatology 2012; 56: 1145-1151.Zelber-Sagi S., Lotan R., Shlomai A., et al. Predictors for incidence and remission of NAFLD in the general population during a sevenyear prospective follow-up. J Hepatology 2012; 56: 1145-1151.Chang Y., Ryu S., Sung E., et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419-1425.Chang Y., Ryu S., Sung E., et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419-1425.Fan J. G., Zhou Q., Wo Q. H. Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2010; 18: 676-679.Fan J. G., Zhou Q., Wo Q. H. Effect of body weight mass and its change on the incidence of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2010; 18: 676-679.Kim H. K., Park J. Y., Lee K. U., et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci. 2009; 337: 98-102.Kim H. K., Park J. Y., Lee K. U., et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci. 2009; 337: 98-102.Rotman Y., Sanyal A.J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017; 66: 180-190.Rotman Y., Sanyal A.J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017; 66: 180-190.Tsai C-J. Steatocholecystitis and fatty gallbladder disease. Dig Dis Sci. 2009; 54(9): 1857-1863.Tsai C-J. Steatocholecystitis and fatty gallbladder disease. Dig Dis Sci. 2009; 54(9): 1857-1863.Everhart J. Contributions of obesity and weight loss to gallstone disease. Annals of internal medicine. 1993; 119(10): 1029-1035.Everhart J. Contributions of obesity and weight loss to gallstone disease. Annals of internal medicine. 1993; 119(10): 1029-1035.Dittrick G., Thompson J., Campos D., et al. Gallbladder pathology in morbid obesity. Obesity surgery. 2005; 15(2): 238-242.Dittrick G., Thompson J., Campos D., et al. Gallbladder pathology in morbid obesity. Obesity surgery. 2005; 15(2): 238-242.Guh D., Zhang W., Bansback N., et al. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9: 88-90.Guh D., Zhang W., Bansback N., et al. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9: 88-90.Tsai C-J., Leitzmann M., Willett W., et al. Prospective study of abdominal adiposity and gallstone disease in US men. The American journal of clinical nutrition. 2004; 80(1): 38-44.Tsai C-J., Leitzmann M., Willett W., et al. Prospective study of abdominal adiposity and gallstone disease in US men. The American journal of clinical nutrition. 2004; 80(1): 38-44.Tsai C-J., Leitzmann M., Willett W., et al. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006; 55(5): 708-14.Tsai C-J., Leitzmann M., Willett W., et al. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006; 55(5): 708-14.Tsai C-J. Steatocholecystitis and fatty gallbladder disease. Dig Dis Sci. 2009; 54(9): 1857-63.Tsai C-J. Steatocholecystitis and fatty gallbladder disease. Dig Dis Sci. 2009; 54(9): 1857-63.Mathus-Vliegen E., Van Ierland-Van Leeu-wen M., Terpstra A. Determinants of gallbladder kinetics in obesity. Dig Dis Sci. 2004; 49(1): 9-16.Mathus-Vliegen E., Van Ierland-Van Leeu-wen M., Terpstra A. Determinants of gallbladder kinetics in obesity. Dig Dis Sci. 2004; 49(1): 9-16.Nakeeb A., Comuzzie A., Al-Azzawi H., et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg. 2006; 10(7): 940-942.Nakeeb A., Comuzzie A., Al-Azzawi H., et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg. 2006; 10(7): 940-942.Tran K., Goldblatt M., Swartz-Basile D., et al. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-re-lated murine obesity. J Gastrointest Surg. 2003; 7(7): 857-860.Tran K., Goldblatt M., Swartz-Basile D., et al. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-re-lated murine obesity. J Gastrointest Surg. 2003; 7(7): 857-860.Cirillo D. J., Wallace R. B., Rodabough R. J., et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330-339.Cirillo D. J., Wallace R. B., Rodabough R. J., et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330-339.Gabbi C., Kim H.J., Barros R., et al. Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc Natl Acad Sci USA. 2010; 107: 14763-14768.Gabbi C., Kim H.J., Barros R., et al. Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc Natl Acad Sci USA. 2010; 107: 14763-14768.Yoo E. H., Lee S. Y. The prevalence and risk factors for gallstone disease. Clin Chem Lab Med. 2009; 47: 795-807.Yoo E. H., Lee S. Y. The prevalence and risk factors for gallstone disease. Clin Chem Lab Med. 2009; 47: 795-807.Stahlberg D., Rudling M., Angelin B., et al. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997; 25: 1447-1450.Stahlberg D., Rudling M., Angelin B., et al. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997; 25: 1447-1450.Di Ciaula A., Portincasa P. Fat, epigenome and pancreatic diseases: interplay and common pathways from a toxic and obesogenic environment. Eur J Intern Med. 2014; 25: 865-73.Di Ciaula A., Portincasa P. Fat, epigenome and pancreatic diseases: interplay and common pathways from a toxic and obesogenic environment. Eur J Intern Med. 2014; 25: 865-73.Hsing A. W., Bai Y., Andreotti G., et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. Int J Cancer. 2007; 121: 832-838.Hsing A. W., Bai Y., Andreotti G., et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. Int J Cancer. 2007; 121: 832-838.Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001; 12: 13-21.Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001; 12: 13-21.Jamal M. M., Yoon E. J., Vega K.J., et al. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J. Gastroenterol. 2009; 15: 5274-5278.Jamal M. M., Yoon E. J., Vega K.J., et al. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J. Gastroenterol. 2009; 15: 5274-5278.Hou L., Xu J., Gao Y. T., et al. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: A population-based study in Shanghai, China. Int J Cancer. 2006; 118: 2847-2853.Hou L., Xu J., Gao Y. T., et al. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: A population-based study in Shanghai, China. Int J Cancer. 2006; 118: 2847-2853.Ji J., Hemminki K. Variation in the risk for liver and gallbladder cancers in socioeconomic and occupational groups in Sweden with etiological implications. Int Arch Occup Environ. Health. 2005; 78: 641-649.Ji J., Hemminki K. Variation in the risk for liver and gallbladder cancers in socioeconomic and occupational groups in Sweden with etiological implications. Int Arch Occup Environ. Health. 2005; 78: 641-649.Moerman C. J., Bueno D.M.H., Runia S. Smoking, alcohol consumption and the risk of cancer of the biliary tract; a population-based case-control study in The Netherlands Eur J Cancer Prev. 1994; 3: 427--36.Moerman C. J., Bueno D.M.H., Runia S. Smoking, alcohol consumption and the risk of cancer of the biliary tract; a population-based case-control study in The Netherlands Eur J Cancer Prev. 1994; 3: 427--36.Tan W., Gao M., Liu N., et al. Body Mass Index and Risk of Gallbladder Cancer: Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2015; 7(10): 8321-8334.Tan W., Gao M., Liu N., et al. Body Mass Index and Risk of Gallbladder Cancer: Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2015; 7(10): 8321-8334.Foster J. M., Hoshi H., Gibbs J. F., et al. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann. Surg. Oncol. 2007; 14: 833-840.Foster J. M., Hoshi H., Gibbs J. F., et al. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann. Surg. Oncol. 2007; 14: 833-840.Hursting S. D., Hursting M.J. Growth signals, inflammation, and vascular perturbations: Mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012; 32: 1766-1770.Hursting S. D., Hursting M.J. Growth signals, inflammation, and vascular perturbations: Mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012; 32: 1766-1770.Dali-Youcef N., Mecili M., Ricci R., et al. Metabolic inflammation: Connecting obesity and insulin resistance. Ann. Med. 2013; 45: 242-253.Dali-Youcef N., Mecili M., Ricci R., et al. Metabolic inflammation: Connecting obesity and insulin resistance. Ann. Med. 2013; 45: 242-253.DeFronzo R. A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14(3): 173-194.DeFronzo R. A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14(3): 173-194.Koh K. K., Han S. H., Quon M. J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005; 46(11): 1978-1985.Koh K. K., Han S. H., Quon M. J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005; 46(11): 1978-1985.Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med. 2006; 38(1): 64-80.Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med. 2006; 38(1): 64-80.Ogilvie R. The island of langerhans in 19 cases of obesity. J Pathol. 1933. 37(3): 473-481.Ogilvie R. The island of langerhans in 19 cases of obesity. J Pathol. 1933. 37(3): 473-481.Olsen T. S. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol. Microbiol. Scand. 1978; 86: 367-673.Olsen T. S. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol. Microbiol. Scand. 1978; 86: 367-673.Stamm B. H. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum. Pathology. 1984; 15: 677-683.Stamm B. H. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum. Pathology. 1984; 15: 677-683.Wu W. C., Wang C. Y. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013; 12: 77-80.Wu W. C., Wang C. Y. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013; 12: 77-80.Van Geenen E.J., Smits M. M., Schreuder T. C., et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas. 2010; 39(8): 1185-1190.Van Geenen E.J., Smits M. M., Schreuder T. C., et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas. 2010; 39(8): 1185-1190.Sasaki M., Nakanuma Y., Ando H. Lipomatous pseudohypertrophy of the pancreas in a patient with cirrhosis due to chronic hepatitis B. Pathol Int. 1998; 48(7): 566-568.Sasaki M., Nakanuma Y., Ando H. Lipomatous pseudohypertrophy of the pancreas in a patient with cirrhosis due to chronic hepatitis B. Pathol Int. 1998; 48(7): 566-568.Diamond I., Vallbona C. Kwashiorkor in a North American white male. Pediatrics. 1960; 25: 248-257.Diamond I., Vallbona C. Kwashiorkor in a North American white male. Pediatrics. 1960; 25: 248-257.Murayama S., Robinson A. E., Mulvihill D. M., et al. MR imaging of pancreas in cystic fibrosis. Pediatr Radiol. 1990; 20(7): 536-539.Murayama S., Robinson A. E., Mulvihill D. M., et al. MR imaging of pancreas in cystic fibrosis. Pediatr Radiol. 1990; 20(7): 536-539.Cubuk M., Arslan G., Ceken K., et al. Shwa-chman-Diamond syndrome. A case report. Acta Radiol. 2000; 41(6): 627-628.Cubuk M., Arslan G., Ceken K., et al. Shwa-chman-Diamond syndrome. A case report. Acta Radiol. 2000; 41(6): 627-628.Lee J. H., Bae S. H., Yu J. J., et al. A case of Shwachman-Diamond syndrome confirmed with genetic analysis in a Korean child. J Korean Med Sci. 2008; 23(1): 142-145.Lee J. H., Bae S. H., Yu J. J., et al. A case of Shwachman-Diamond syndrome confirmed with genetic analysis in a Korean child. J Korean Med Sci. 2008; 23(1): 142-145.Daentl D. L., Frias J. L., Gilbert E. F., et al. The Johanson-Blizzard syndrome: case report and autopsy findings. Am J Med Genet. 1979; 3(2): 129-135.Daentl D. L., Frias J. L., Gilbert E. F., et al. The Johanson-Blizzard syndrome: case report and autopsy findings. Am J Med Genet. 1979; 3(2): 129-135.Raeder H, Haldorsen I. S., Ersland L., Gruner R., et al. Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-esterlipase. Diabetes. 2007; 56(2): 444-449.Raeder H, Haldorsen I. S., Ersland L., Gruner R., et al. Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-esterlipase. Diabetes. 2007; 56(2): 444-449.Carter R., Mouralidarane A., Soeda J., et al. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. PLoS One. 2014; 9(3): 10-12.Carter R., Mouralidarane A., Soeda J., et al. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. PLoS One. 2014; 9(3): 10-12.Ferlay J., Shin H-R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLO-BOCAN2008. Int J Cancer. 2010; 127(12): 2893-2917.Ferlay J., Shin H-R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLO-BOCAN2008. Int J Cancer. 2010; 127(12): 2893-2917.Aune D., Greenwood D., Chan D., et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear doseresponse meta-analysis of prospective studies. Annals of oncology: official journal of the European Society for Medical Oncology. 2012; 23(4): 843-52.Aune D., Greenwood D., Chan D., et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear doseresponse meta-analysis of prospective studies. Annals of oncology: official journal of the European Society for Medical Oncology. 2012; 23(4): 843-52.Pinnick K. E. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring). 2008; 16: 522-530.Pinnick K. E. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring). 2008; 16: 522-530.Rossi A. P., Fantin F., Zamboni G. A. et al. Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutrit. Diabet. 2012; 2: 32-35.Rossi A. P., Fantin F., Zamboni G. A. et al. Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutrit. Diabet. 2012; 2: 32-35.Ferlay J., Soerjomataram I., Ervik M., et al. Cancer Incidence and Mortality Worldwide. IARC CancerBase. GLOBOCAN. 2015; 136(5): 359-386.Ferlay J., Soerjomataram I., Ervik M., et al. Cancer Incidence and Mortality Worldwide. IARC CancerBase. GLOBOCAN. 2015; 136(5): 359-386.Siegel R., Ma J., Zou Z., Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29.Siegel R., Ma J., Zou Z., Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9-29.Sedjo R. L., Byers T., Levin T. R., et al. Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007; 16(3): 526-531.Sedjo R. L., Byers T., Levin T. R., et al. Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007; 16(3): 526-531.Jacobs E. T., Ahnen D. J., Ashbeck E. L., et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 2009 Mar 15; 169(6): 657-666.Jacobs E. T., Ahnen D. J., Ashbeck E. L., et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 2009 Mar 15; 169(6): 657-666.Kim M. C., Jung S. W., Kim C. S., et al. Metabolic syndrome is associated with increased risk of recurrent colorectal adenomas in Korean men. Int J Obes (Lond). 2012 Jul; 36(7): 1007-1011.Kim M. C., Jung S. W., Kim C. S., et al. Metabolic syndrome is associated with increased risk of recurrent colorectal adenomas in Korean men. Int J Obes (Lond). 2012 Jul; 36(7): 1007-1011.Laiyemo A. O., Doubeni C., Badurdeen D. S., et al. Obesity, weight change, and risk of adenoma recurrence: a prospective trial. Endoscopy. 2012; 44(9): 813-818.Laiyemo A. O., Doubeni C., Badurdeen D. S., et al. Obesity, weight change, and risk of adenoma recurrence: a prospective trial. Endoscopy. 2012; 44(9): 813-818.Kono S., Handa K., Hayabuchi H., et al. Obesity, weight gain and risk of colon adenomas in Japanese men. Jpn J Cancer Res. 1999; 90(8): 805-811.Kono S., Handa K., Hayabuchi H., et al. Obesity, weight gain and risk of colon adenomas in Japanese men. Jpn J Cancer Res. 1999; 90(8): 805-811.Gallagher E. J., LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011; 152(7): 2546-2551.Gallagher E. J., LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011; 152(7): 2546-2551.Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6): 2208-2225.Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6): 2208-2225.Bardou M., Barkun A. N., Martel M. Obesity and colorectal cancer. Gut. 2013; 62(6): 933-947.Bardou M., Barkun A. N., Martel M. Obesity and colorectal cancer. Gut. 2013; 62(6): 933-947.Shen J., Obin M.S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013; 34(1): 39-58.Shen J., Obin M.S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013; 34(1): 39-58.Aleman J. O., Eusebi L. H., Ricciardiello L., et al. Mechanisms of obesityinduced gastrointestinal neoplasia. Gastroenterology. 2014; 146(2): 357-373.Aleman J. O., Eusebi L. H., Ricciardiello L., et al. Mechanisms of obesityinduced gastrointestinal neoplasia. Gastroenterology. 2014; 146(2): 357-373.Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. 2014; 1: 21-23.Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. 2014; 1: 21-23.Ohtani N., Yoshimoto S., Hara E. Obesity and cancer: a gut microbial connection. Cancer Res. 2014; 74(7): 1885-1889.Ohtani N., Yoshimoto S., Hara E. Obesity and cancer: a gut microbial connection. Cancer Res. 2014; 74(7): 1885-1889.Sandhu M. S., Dunger D. B., Giovannuc-ci E. L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002; 94(13): 972-980.Sandhu M. S., Dunger D. B., Giovannuc-ci E. L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002; 94(13): 972-980.Jiang B., Zhang X., Du L. L., et al. Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer. World J Gastroenterol. 2014; 20(6): 1608-1613.Jiang B., Zhang X., Du L. L., et al. Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer. World J Gastroenterol. 2014; 20(6): 1608-1613.Comstock S.S., Hortos K., Kovan B., et al. Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study. PLoS One. 2014; 9(1): 510-522.Comstock S.S., Hortos K., Kovan B., et al. Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study. PLoS One. 2014; 9(1): 510-522.Wang D., Chen J., Chen H., et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/ mTOR signalling pathway. J Biosci. 2012; 37(1): 91-101.Wang D., Chen J., Chen H., et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/ mTOR signalling pathway. J Biosci. 2012; 37(1): 91-101.Endo H., Hosono K., Uchiyama T., et al. Leptin acts as a growth factor for colorectal tumours at stages subsequen t to tumour initiation in murine colon carcinogenesis. Gut. 2011; 60(10): 1363-1371.Endo H., Hosono K., Uchiyama T., et al. Leptin acts as a growth factor for colorectal tumours at stages subsequen t to tumour initiation in murine colon carcinogenesis. Gut. 2011; 60(10): 1363-1371.Stocks T., Lukanova A., Bjørge T., et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me- Can). Cancer. 2011; 117(11): 2398-2407.Stocks T., Lukanova A., Bjørge T., et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me- Can). Cancer. 2011; 117(11): 2398-2407.Ahmed R. L., Schmitz K. H., Anderson K. E., et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107(1): 28-36.Ahmed R. L., Schmitz K. H., Anderson K. E., et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107(1): 28-36.Almendingen K., Hofstad B., Vatn M. H. Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol. 2001; 96(7): 2238-2246.Almendingen K., Hofstad B., Vatn M. H. Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol. 2001; 96(7): 2238-2246.Yamaji Y., Okamoto M., Yoshida H., et al. The effect of body weight reduction on the incidence of colorectal adenoma. Am J Gastroenterol. 2008; 103(8): 2061-2067.Yamaji Y., Okamoto M., Yoshida H., et al. The effect of body weight reduction on the incidence of colorectal adenoma. Am J Gastroenterol. 2008; 103(8): 2061-2067.Larsson S. C., Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007; 86(3): 556-565.Larsson S. C., Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007; 86(3): 556-565.Pischon T., Lahmann P. H., Boeing H., et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006; 98(13): 920-931.Pischon T., Lahmann P. H., Boeing H., et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006; 98(13): 920-931.Keimling M., Renehan A. G., Behrens G., et al. Comparison of associations of body mass index, abdominal adiposity, and risk of colorectal cancer in a large prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013 Aug; 22(8): 1383-1394.Keimling M., Renehan A. G., Behrens G., et al. Comparison of associations of body mass index, abdominal adiposity, and risk of colorectal cancer in a large prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013 Aug; 22(8): 1383-1394.Moore L. L., Bradlee M. L., Singer M. R., et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord. 2004; 28(4): 559-567.Moore L. L., Bradlee M. L., Singer M. R., et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord. 2004; 28(4): 559-567.Dai Z., Xu Y. C., Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007; 13(31): 4199-4206.Dai Z., Xu Y. C., Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007; 13(31): 4199-4206.Wang Y., Jacobs E. J., Patel A. V., et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control. 2008; 19(7): 783-792.Wang Y., Jacobs E. J., Patel A. V., et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control. 2008; 19(7): 783-792.Brändstedt J., Wangefjord S., Nodin B. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol Sex Differ. 2012; 3(1): 23-25.Brändstedt J., Wangefjord S., Nodin B. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol Sex Differ. 2012; 3(1): 23-25.Li H., Yang G., Xiang Y. B., et al. Body weight, fat distribution and colorectal cancer risk: a report from cohort studies of 134255 Chinese men and women. Int J Obes (Lond). 2012; 28(4): 560-561.Li H., Yang G., Xiang Y. B., et al. Body weight, fat distribution and colorectal cancer risk: a report from cohort studies of 134255 Chinese men and women. Int J Obes (Lond). 2012; 28(4): 560-561.Akiyoshi T., Ueno M., Fukunaga Y., et al. Effect of body mass index on short-term outcomes of patients undergoing laparoscopic resection for colorectal cancer: a single institution experience in Japan. Surg Laparosc Endosc Percutan Tech. 2011; 21(6): 409-414.Akiyoshi T., Ueno M., Fukunaga Y., et al. Effect of body mass index on short-term outcomes of patients undergoing laparoscopic resection for colorectal cancer: a single institution experience in Japan. Surg Laparosc Endosc Percutan Tech. 2011; 21(6): 409-414.Amri R., Bordeianou L. G., Sylla P., et al. Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancersurgery. Am J Surg. 2014; 207(1): 17-23.Amri R., Bordeianou L. G., Sylla P., et al. Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancersurgery. Am J Surg. 2014; 207(1): 17-23.Hawkins A. T., Berger D. L., Shellito P. C., et al. Wound dehiscence after abdominoperineal resection for low rectal cancer is associated with decreased survival. Dis Colon Rectum. 2014; 57(2): 143-150.Hawkins A. T., Berger D. L., Shellito P. C., et al. Wound dehiscence after abdominoperineal resection for low rectal cancer is associated with decreased survival. Dis Colon Rectum. 2014; 57(2): 143-150.Steins Bisschop C. N., van Gils C. H., Emaus M. J., et al. Weight change later in life and colon and rectal cancer risk in participants in the EPICPANACEA study. Am J Clin Nutr. 2014; 99(1): 139-147.Steins Bisschop C. N., van Gils C. H., Emaus M. J., et al. Weight change later in life and colon and rectal cancer risk in participants in the EPICPANACEA study. Am J Clin Nutr. 2014; 99(1): 139-147.

The authors declare that there are no conflicts of interest present.